Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.530
-0.040 (-2.55%)
At close: Apr 9, 2026, 4:00 PM EDT
1.530
0.00 (0.00%)
After-hours: Apr 9, 2026, 4:10 PM EDT
Rein Therapeutics Employees
Rein Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$4,987,100
Market Cap
42.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Werewolf Therapeutics | 39 |
| Lisata Therapeutics | 21 |
| Atossa Therapeutics | 15 |
| Sensei Biotherapeutics | 15 |
| Rallybio | 14 |
| Nutriband | 13 |
| RenovoRx | 10 |
RNTX News
- 5 months ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 6 months ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 7 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 8 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 8 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 10 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 10 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 11 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire